Dinitrochlorobenzene is inherently mutagenic in the presence of trace mutagenic contaminants.
M G Wilkerson, T H Connor, J K Wilkin
Index: Arch. Dermatol. 124(3) , 396-8, (1988)
Full Text: HTML
Abstract
2,4-Dinitrochlorobenzene (DNCB) is used for immunotherapy of alopecia areata and verruca vulgaris. We initially postulated that the presence of mutagenic contaminants in commercially available DNCB might account for part of its mutagenicity. We have now characterized changes in the dose-mutagenic response curve of 99% DNCB modified by adding 1% concentrations of known contaminants: 1-chloro-2-nitrobenzene; 1,3-dinitrobenzene; and 2,4-dichloronitrobenzene. Dose-response curves were generated using Salmonella typhimurium tester strains TA-98 and TA-100 at concentrations of 0, 1, 5, 10, 25, 50, and 100 micrograms per plate in a modified Ames assay. We observed a linear dose-response relationship with a slight, but nonsignificant, shift to the right when contaminants were added. We conclude that DNCB is itself mutagenic, and that contaminants play a minor role in its observed mutagenicity.
Related Compounds
Related Articles:
1987-07-01
[Br. J. Dermatol. 117(1) , 1-9, (1987)]
Contribution of caffeine and flavanols in the induction of hepatic Phase II activities by green tea.
1998-08-01
[Food Chem. Toxicol. 36(8) , 617-21, (1998)]
Dose-response effects of lycopene on selected drug-metabolizing and antioxidant enzymes in the rat.
2000-06-30
[Cancer Lett. 154(2) , 201-10, (2000)]
2007-06-01
[Toxicol. In Vitro 21(4) , 723-33, (2007)]
2008-08-01
[Toxicol. In Vitro 22(5) , 1169-76, (2008)]